January 16, 2022

Beyond Going Long

Complete UK News World

New study results: Second dose is ineffective against Omigran!  One thing is important

New study results: Second dose is ineffective against Omigran! One thing is important

The most widely used Pfizer and AstraZeneca in the UK show reduced performance. However, the office warns that these are only preliminary results. In its analysis, the UK HSA focuses on several hundred cases of omigran infection and several thousand cases of delta infection.

Source: TASR / AP / Darko Vojinovic

The study points to a significant decrease in the effectiveness of the Pfizer vaccine in the Omigron variant compared to the delta variant. In the case of the AstraZeneca vaccine, the BBC describes the decline in performance as ‘dramatic’. There is not enough data in the office for Johnson & Johnson & Moderna’s two other vaccines.

New study results: Second

Zdroj: SITA / AP Photo / Christophe Ena

The third dose is important

“Preliminary data show that the effectiveness against the new variant (Omigron) increases significantly after restoration and that protection against symptomatic disease reaches 70 to 75 percent.” The report said. The office added that protection against the severe course of Kovit-19 disease would be even higher.

New study results: Second

Source: TASR / AP Photo / Markus Schreiber

“However, due to the preliminary nature of the findings, all estimates are highly uncertain and may change.” Warning message. More than 22 million people in the UK have received the booster dose, which is half of the 46 million people who have been vaccinated. Covit-19 vaccine coverage in the UK is 70 percent.

British officials said on Friday that more than 400 new Omigron variants had been detected the previous day, and that the total number of people affected by the variation had exceeded 1,200 in the country. According to UK HSA estimates the new variant will be up to half of the daily increase in the coming weeks. Authorities registered 58,000 new cases on Friday, the highest number since the beginning of January.

See also  Britain has extended the administration of a third dose of the vaccine to everyone from the age of 18